Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: A short-term time course study in patients with stable angina

Clinica Chimica Acta

Volumn 352, Issue 1-2, 2005, Pages 217-224

  Li, Jian Jun ^a   Hu, Sheng Shou ^a   Fang, Chun Hong ^b   Hui, Rui Tai ^a   Miao, Li Fu ^c   Yang, Yue Jin ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

C reactive protein; Lipid profile; Stable angina; Xuezhikang

Indexed keywords

C REACTIVE PROTEIN; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; EXTRACT; FEMALE; HUMAN; MALE; OBSERVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; STABLE ANGINA PECTORIS;

ADULT; ANGINA PECTORIS; BIOLOGICAL PRODUCTS; C-REACTIVE PROTEIN; CHOLESTEROL; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; TIME FACTORS;

ANGINA;

EID: 11844269827     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.09.026     Document Type: Article

References (36)

1. A. Maseri Inflammation, atherosclerosis and ischemic events: exploring the hidden side of the moon N. Engl. J. Med. 336 1997 1014 1016
2. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1993 115 126
3. P. Libby, and P.M. Ridker Novel inflammatory markers of coronary risk: theory versus practice Circulation 100 1999 1148 1150
4. J.-J. Li, and C.-H. Fang C-reactive protein is not only a marker but also direct cause of cardiovascular disease Med. Hypotheses 62 2004 499 506
5. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin and risks of cardiovascular disease in apparently healthy men N. Engl. J. Med. 336 1997 973 979
6. J.-J. Li, H. Jiang, C.-X. Huang, C.-H. Fang, Q.-Z. Tang, and H. Xia Elevated levels of plasma C-reactive protein in patients with unstable angina: its relations with coronary stenosis and lipid profile Angiology 53 2002 265 272
7. J.-J. Li, C.-H. Fang, M.-Z. Cheng, X. Chen, and S.W.L. Lee Activation of nuclear factor-κB and correlation with increased plasma C-reactive protein in patients with unstable angina Heart Lung Circ. 13 2004 173 178
8. G. Liuzzo, L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, and M.B. Pepys The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N. Engl. J. Med. 331 1994 417 424
9. D.A. Morrow, N. Rifai, and E.M. Antman C-reactive protein is a potent predicator of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy J. Am. Coll. Cardiol. 31 1998 1460 1465
10. H.K. Meier-Ewert, P.M. Ridker, N. Rifai, N. Price, D.F. Dinges, and J.M. Mullington Absence of diurnal variation of C-reactive protein levels in healthy human subjects Clin. Chem. 47 2001 444 450
11. I.S. Ockene, C.E. Matthews, N. Rifai, P.M. Ridker, G. Reed, and E. Stanek Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults Clin. Chem. 47 2001 444 450
12. J.K. Plenge, T.L. Hernandez, K.M. Weil, P. Poirier, G.K. Grunwald, and S.M. Marcovina Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation 106 2002 1447 1452
13. J.-J. Li, M.-Z. Chen, X. Chen, and C.-H. Fang Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia Clin. Cardiol. 26 2003 472 476
14. J.-J. Li, and X.-J. Chen Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide Coron. Artery Dis. 14 2003 329 334
15. G. Jackson The role of statins in acute coronary syndromes: managing the unmet need Int. J. Clin. Pract. 54 2000 445 449
16. T.D. Szucs Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price? Eur. Heart J. 19 Suppl. M 1998 M22 M28
17. K. Fairhurst, and G. Huby From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia BMJ 317 1998 1130 1134
18. R.R. Azar, D.D. Waters, and B. Lebanon PRINCE's prospects: statin, inflammation, and coronary risk Am. Heart J. 141 2001 881 883
19. C.B. Treasure, J.L. Klein, W.S. Weintraub, J.D. Talley, M.E. Stillabower, and A.S. Rosinski Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease N. Engl. J. Med. 332 1995 481 487
20. H.G. Schrott, H. Knapp, M. Davila, L. Shurzinske, and D. Black Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study Am. Heart J. 140 2000 249 252
21. J. Dupuis, J. Tardif, P. Cernacek, and P. Theroux Cholesterol reduction rapidly improves endothelial function after acute coronary syndrome J. Am. Coll. Cardiol. 31 1998 891 896
22. H.R. Arntz, W. Wunderlich, and L. Schnitzer The decisive importance of cholesterol lowering therapy for coronary lesion and clinical course immediately after an acute coronary event: short and long-term results of a controlled study Circulation 98 Suppl. 1 1998 1 45
23. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald For the cholesterol and recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein Circulation 100 1999 230 235
24. M. Miller, C. Dolinor, W. Cromwell, and J.D. Otvos Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia Am. J. Cardiol. 87 2001 223 232
25. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction in C-reactive with cerivastatin among 785 patients with primary hypercholesterolemia Circulation 103 2001 1191 1193
26. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein Circulation 100 1999 230 235
27. D. Heber, I. Yin, J.M. Ashley, D.A. Elashoff, R.M. Elashoff, and W.L. Gio Cholesterol-lowering effects of a proprietary Chinese red yeast-rice dietary supplement Am. J. Clin. Nutr. 69 1999 231 236
28. L. Liu, S.P. Zhao, Y.-C. Cheng, and Y.-L. Li Xuezhikang decreases serum lipoprotein (a) and C-reactive protein concentrations in patients with coronary heart disease Clin. Chem. 49 2003 1347 1353
29. S.-P. Zhao, L. Liu, Y.-C. Cheng, and Y.-L. Li Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease Atherosclerosis 168 2003 375 380
30. S.P. Zhao, L. Liu, Y.C. Cheng, M.H. Shishehbor, M.H. Liu, and D.Q. Peng Xuezhiknag, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease Circulation 110 2004 915 920
31. J.-J. Li, C.-X. Huang, H. Jiang, C.-H. Fang, F. Chen, and Q.-Z. Tang Circadian Variation in ischemic threshold in patients with stable angina: relation to plasma endothelin-1 Angiology 53 2002 409 413
32. J.-J. Li, C.-X. Huang, H. Jiang, C.-H. Fang, F. Chen, and Q.-Z. Tang Ischemic preconditioning detected by treadmill exercise tests in patients with stable angina Angiology 54 2003 45 50
33. G.C. Gensini A more meaningful scoring system for determining the severity of coronary heart disease Am. J. Cardiol. 51 1983 606
34. H.G. Schrott, V. Bittner, E. Vittinghoff, D.M. Herrington, and S. Hurley Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: the Heart and Estrogestin Replacement Study (HERS) JAMA 277 1997 1281 1286
35. H.H. Knapp, H. Schrott, P. Ma, R. Knopp, B. Chin, and J.M. Gaziano Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia Am. J. Med. 110 2001 352 360
36. R.G. Reed, S.Y. Fong, and T.A. Pearson Role of a central laboratory in implementing National Cholesterol Education Panel guidelines in rural practices: model system for managed care Clin. Chem. 41 1995 271 274